MAIA Biotechnology (MAIA) Accumulated Expenses (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Accumulated Expenses for 6 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 172.01% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 172.01% YoY), while the FY2025 annual figure was $3.8 million, up 63.86% from the prior year.
• Accumulated Expenses fell to $3.3 million in Q1 2026 per MAIA's latest filing, from $3.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.8 million in Q4 2025 and bottomed at $448443.0 in Q2 2024.
• Historically, Accumulated Expenses has averaged $1.9 million across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 73.98% — and 2025, when it soared 640.52%.
• MAIA Biotechnology's Accumulated Expenses stood at $2.1 million in 2022, then sank by 62.58% to $786999.0 in 2023, then surged by 194.49% to $2.3 million in 2024, then jumped by 63.86% to $3.8 million in 2025, then slipped by 12.07% to $3.3 million in 2026.
• Business Quant data shows MAIA's Accumulated Expenses at $3.3 million in Q1 2026, $3.8 million in Q4 2025, and $899931.0 in Q3 2025.